Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2003-07-02
Target enrollment:
Participant gender:
Summary
Current therapies for Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma
provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston
therapy suggest that it may prove beneficial in the treatment of Refractory or Recurrent
High-Grade Stage II - IV Non-Hodgkin's Lymphoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Refractory or Recurrent High-Grade Stage II - IV
Non-Hodgkin's Lymphoma.